MDT

95.61

+0.82%↑

VEEV

300.34

+2.34%↑

138.64

-0.03%↓

HQY

89.66

-1.24%↓

PHR.US

22.83

+1.69%↑

MDT

95.61

+0.82%↑

VEEV

300.34

+2.34%↑

138.64

-0.03%↓

HQY

89.66

-1.24%↓

PHR.US

22.83

+1.69%↑

MDT

95.61

+0.82%↑

VEEV

300.34

+2.34%↑

138.64

-0.03%↓

HQY

89.66

-1.24%↓

PHR.US

22.83

+1.69%↑

MDT

95.61

+0.82%↑

VEEV

300.34

+2.34%↑

138.64

-0.03%↓

HQY

89.66

-1.24%↓

PHR.US

22.83

+1.69%↑

MDT

95.61

+0.82%↑

VEEV

300.34

+2.34%↑

138.64

-0.03%↓

HQY

89.66

-1.24%↓

PHR.US

22.83

+1.69%↑

Inicio・Lista de Acciones・Adaptive Biotechnologies Corp

Adaptive Biotechnologies Corp

Cerrado

14.2 -2.41

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

14.01

Máximo

14.59

Métricas clave
By Trading Economics
Ingresos	4.2M -26M
Ventas	6.4M 59M
Margen de beneficios	-43.467
Empleados	619
EBITDA	11M -18M

Recomendaciones
By TipRanks
Recomendaciones	Compra Fuerte
Estimación a 12 Meses	+3.02% upside

Dividendos
By Dow Jones
Próximas Ganancias	6 nov 2025

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	392M 2B
Apertura anterior	16.61
Cierre anterior	14.2

Puntuación técnica

By Trading Central

Confianza

Very Strong Bullish Evidence

8.81 / 10.18 Soporte y Resistencia

Adaptive Biotechnologies Corp Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

2 oct 2025, 23:30 UTC

Acciones populares

Stocks to Watch: Rumble, Applied Materials, American Outdoor Brands

2 oct 2025, 21:21 UTC

Ganancias

Applied Materials Expects New Export Rule to Hit 2026 Revenue by $600 Million

3 oct 2025, 00:00 UTC

Adquisiciones, fusiones, absorciones

Warren Buffett's Berkshire Comes to the Aid of Occidental Petroleum -- Again -- WSJ

2 oct 2025, 23:40 UTC

Charlas de Mercado

Gold Edges Higher, Aided by Risks U.S. Shutdown May Weaken Economy -- Market Talk

2 oct 2025, 23:39 UTC

Charlas de Mercado

Japanese Stocks May Edge Higher, Tracking Wall Street Gains -- Market Talk

2 oct 2025, 23:29 UTC

Adquisiciones, fusiones, absorciones

Vistra: Transaction Remains on Track to Close This Qtr or 1Q 2026 >VST

2 oct 2025, 23:29 UTC

Adquisiciones, fusiones, absorciones

Vistra: Received Regulatory Approval From FERC for Acquisition of Certain Subsidiaries Owning Seven Natural-Gas Generation Facilities From Lotus Infrastructure Partners >VST

2 oct 2025, 23:29 UTC

Adquisiciones, fusiones, absorciones

Vistra: Next Step in Acquisition of Gas Generation Fleet With Approval From Federal Energy Regulatory Commission

2 oct 2025, 23:00 UTC

Charlas de Mercado

Warehouse Needs Time to Restore Credibility With Investors -- Market Talk

2 oct 2025, 22:54 UTC

Charlas de Mercado

Adquisiciones, fusiones, absorciones

Scales's JV Buyout Lauded by Bull -- Market Talk

2 oct 2025, 22:54 UTC

Charlas de Mercado

Adquisiciones, fusiones, absorciones

Global Forex and Fixed Income Roundup: Market Talk

2 oct 2025, 22:46 UTC

Charlas de Mercado

Synlait Milk Loses Bear Following Sale of North Island Assets -- Market Talk

2 oct 2025, 22:46 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

2 oct 2025, 21:17 UTC

Adquisiciones, fusiones, absorciones

Buffett Scores Win in Berkshire's Deal for Occidental Chemicals Unit -- Barrons.com

2 oct 2025, 20:50 UTC

Charlas de Mercado

Adquisiciones, fusiones, absorciones

Energy & Utilities Roundup: Market Talk

2 oct 2025, 20:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

2 oct 2025, 20:49 UTC

Adquisiciones, fusiones, absorciones

OpenAI's Latest Funding Deal Returns Focus to AI Economy, Lifting U.S. Stocks -- WSJ

2 oct 2025, 20:00 UTC

Adquisiciones, fusiones, absorciones

Legrand Signs Definitive Agreement To Acquire Avtron Power Solutions, A Global Provider Of Load Banks & Power Quality Solutions >LR.FR

2 oct 2025, 19:20 UTC

Charlas de Mercado

Natural Gas Snaps Winning Streak Despite Small Inventory Rise -- Market Talk

2 oct 2025, 19:10 UTC

Charlas de Mercado

Bank of Canada to Publish Inflation Dashboard in 2026 -- Market Talk

2 oct 2025, 19:04 UTC

Charlas de Mercado

Oil Futures Extend Losses as Markets Brace for Higher Output -- Market Talk

2 oct 2025, 18:46 UTC

Adquisiciones, fusiones, absorciones

Honeywell: Transaction Expected to Improve Annual Free Cash Flow by More Than $100 M Over Next Several Years and Then Decrease Over Time >HON

2 oct 2025, 18:46 UTC

Adquisiciones, fusiones, absorciones

Honeywell: Loss Will Be Excluded From Adjusted EPS >HON

2 oct 2025, 18:46 UTC

Adquisiciones, fusiones, absorciones

Honeywell: Estimated Impact of Divestiture Will Be One-Time Loss of About $115 M >HON

2 oct 2025, 18:45 UTC

Adquisiciones, fusiones, absorciones

Honeywell Will Have No Further Fincl Exposure to the Transferred Liabilities >HON

2 oct 2025, 18:45 UTC

Adquisiciones, fusiones, absorciones

Honeywell Utilized Portion of Cash From Resideo Indemnification and Reimbursement Agreement Termination to Fund Delticus Transaction >HON

2 oct 2025, 18:44 UTC

Adquisiciones, fusiones, absorciones

Honeywell: Delticus Assumed Full Responsibility for Administering and Resolving All Current and Future Asbestos-Related Claims >HON

2 oct 2025, 18:44 UTC

Adquisiciones, fusiones, absorciones

Honeywell and Delticus Contributed About $1.68 B in Cash, as Well as Certain Insurance Assets Related to Legacy Asbestos Liabilities >HON

2 oct 2025, 18:44 UTC

Adquisiciones, fusiones, absorciones

Honeywell: Transaction Strengthens Annual Free Cash Flow Generation >HON

2 oct 2025, 18:43 UTC

Adquisiciones, fusiones, absorciones

Honeywell Divested All Legacy Bendix Asbestos Liabilities, as Well as Certain Non-Bendix Asbestos Liabilities, to Delticus >HON

Comparación entre iguales

Cambio de precio

Adaptive Biotechnologies Corp previsión

Precio Objetivo

By TipRanks

3.02% repunte

Estimación a 12 Meses

Media 15 USD 3.02%

Máximo 20 USD

Mínimo 11 USD

De acuerdo con 8 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Adaptive Biotechnologies Corp Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

8 ratings

Comprar

Mantener

Vender

De acuerdo con 8 analistas que ofrecen calificaciones bursátiles a para Adaptive Biotechnologies Corp Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

8.81 / 10.18Soporte y Resistencia

Recent bullish events outweigh bearish events.

All events are bullish.

There is one bullish event.

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Adaptive Biotechnologies Corp

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.